Gammaherpesvirus Colonization of the Spleen Requires Lytic Replication in B Cells
Overview
Affiliations
Gammaherpesviruses infect lymphocytes and cause lymphocytic cancers. Murid herpesvirus-4 (MuHV-4), Epstein-Barr virus, and Kaposi's sarcoma-associated herpesvirus all infect B cells. Latent infection can spread by B cell recirculation and proliferation, but whether this alone achieves systemic infection is unclear. To test the need of MuHV-4 for lytic infection in B cells, we flanked its essential ORF50 lytic transactivator with sites and then infected mice expressing B cell-specific Cre (CD19-Cre). The floxed virus replicated normally in Cre mice. In CD19-Cre mice, nasal and lymph node infections were maintained; but there was little splenomegaly, and splenic virus loads remained low. Cre-mediated removal of other essential lytic genes gave a similar phenotype. CD19-Cre spleen infection by intraperitoneal virus was also impaired. Therefore, MuHV-4 had to emerge lytically from B cells to colonize the spleen. An important role for B cell lytic infection in host colonization is consistent with the large CD8 T cell responses made to gammaherpesvirus lytic antigens during infectious mononucleosis and suggests that vaccine-induced immunity capable of suppressing B cell lytic infection might reduce long-term virus loads. Gammaherpesviruses cause B cell cancers. Most models of host colonization derive from cell cultures with continuous, virus-driven B cell proliferation. However, vaccines based on these models have worked poorly. To test whether proliferating B cells suffice for host colonization, we inactivated the capacity of MuHV-4, a gammaherpesvirus of mice, to reemerge from B cells. The modified virus was able to colonize a first wave of B cells in lymph nodes but spread poorly to B cells in secondary sites such as the spleen. Consequently, viral loads remained low. These results were consistent with virus-driven B cell proliferation exploiting normal host pathways and thus having to transfer lytically to new B cells for new proliferation. We conclude that viral lytic infection is a potential target to reduce B cell proliferation.
Perdrizet U, Hill J, Sobchishin L, Singh B, Fernando C, Bollinger T Vet Pathol. 2024; 61(4):550-561.
PMID: 38619093 PMC: 11264566. DOI: 10.1177/03009858241244849.
Gupta A, Owens S, Oldenburg D, White D, Forrest J J Virol. 2022; 96(12):e0069022.
PMID: 35647668 PMC: 9215232. DOI: 10.1128/jvi.00690-22.
Cieniewicz B, Kirillov V, Daher I, Li X, Oldenburg D, Dong Q J Virol. 2022; 96(10):e0002722.
PMID: 35481781 PMC: 9131860. DOI: 10.1128/jvi.00027-22.
Conquering the Host: Determinants of Pathogenesis Learned from Murine Gammaherpesvirus 68.
Wang Y, Tibbetts S, Krug L Annu Rev Virol. 2021; 8(1):349-371.
PMID: 34586873 PMC: 9153731. DOI: 10.1146/annurev-virology-011921-082615.
Brar G, Farhat N, Sukhina A, Lam A, Kim Y, Hsu T NPJ Vaccines. 2020; 5(1):102.
PMID: 33298958 PMC: 7644650. DOI: 10.1038/s41541-020-00251-x.